US Markets
Home›US Markets›M&A & Deals›AstraZeneca weighs a potential Bristol Myers Squibb me…
AstraZeneca weighs a potential Bristol Myers Squibb mega-merger
Coverage notes AstraZeneca shares have fallen 8.9% amid the talks, and any deal could add substantial debt as it targets a rival with a patent cliff.
The Guardian Business discusses AstraZeneca CEO Pascal Soriot and argues the company should focus on its existing strategy of supplementing internal development with licensing and partnerships rather than pursuing a very large US combination. The outlet says the drugmaker is in talks regarding a merger with Bristol Myers Squibb, a deal it frames as a potential $400 billion mega-merger. It also questions the business rationale, including how AstraZeneca would address the takeover premium and cost base to justify the transaction. The article highlights that AstraZeneca has historically been skeptical of large corporate exercises and suggests the discussions could be quietly dropped in the absence of any company confirmation. It also flags that a $133 billion acquisition of the rival would likely come with a significant debt component. Finally, the piece points to the patent cliff risk AstraZeneca would inherit, noting Bristol Myers Squibb sales of its Opdivo cancer treatment are expected to plunge between now and 2030. Jefferies is cited as saying AstraZeneca does not need financial engineering in its view, while the article adds that the merger would expose AstraZeneca to that product trajectory.